Phadia je novým corporátním členem EDMA

Phadia Joins EDMA Corporate Membership

EDMA, the European Diagnostic Manufacturers Association, welcomes Phadia as a new corporate affiliate, bringing the Association’s overall membership up to 35 major IVD companies and 22 National Associations. Phadia is active in the field of clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases.

The operations started in Pharmacia’s diagnostics group in 1967, but it is in 2004 that Pharmacia Diagnostics was established as a new, independent company, and in 2006 that the company adopted the name Phadia. The research and development of Phadia is carried out at its headquarters in Uppsala, Sweden as well as in Freiburg, Germany. Phadia’s allergy related work in Uppsala is focused on the early identification of patients at risk, and the first signs of a developing inflammation and asthma. The research conducted at the Freinburg centre within the field of autoimmunity is focused on molecular biology and is carried out in close cooperation with internationally well-known scientific groups.

As an active member in the international scientific and clinical communities, Phadia is committed to research and development in order to uphold its mission of the advancement of knowledge.

EDMA looks forward to cooperating with Phadia in order to promote In Vitro testing, prevention, early diagnosis and monitoring of treatments, access to innovation, and high quality healthcare.

Background:
EDMA, the European Diagnostic Manufacturers Association represents National Associations and major companies engaged in the research, development, manufacture or distribution of In Vitro Diagnostic (IVD) medical devices in Europe. Through its affiliated National Associations, EDMA represents in total more than 500 companies (or over 700 legal entities) across Europe. The mission of EDMA is to raise awareness of the importance, usefulness and added-value that diagnostic information can provide to healthcare. For this purpose, EDMA cooperates with European institutions, patients groups, trade associations, health professionals and academia to support an appropriate regulatory system, to work towards a realistic economic environment for healthcare in Europe and to be an effective voice in globalisation.